Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: A prospective, open-label, pilot study

Urology

Volumn 62, Issue 5, 2003, Pages 922-927

  Caruso, Salvatore ^a   Intelisano, Giorgia ^b   Farina, Marco ^b   Di Mari, Lucia ^b   Agnello, Carmela ^b   Giammusso, Bruno ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER FLOWMETRY; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; HYPERPROLACTINEMIA; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; VERTIGO; VOMITING;

EID: 0242580166     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00694-0     Document Type: Article

References (30)

1. Kaiser F.E. Sexuality and impotence in the aging man. Clin Geriatr Med. 7:1991;63-72.
2. Melman A., Gingell J.C. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 161:1999;5-11.
3. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old longitudinal results from the Massachusetts Male Aging Study. J Urol. 163:2000;460-463.
4. Ayta I.A., McKinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 84:1999;50-56.
5. Mulhall J.P. Current concepts in erectile dysfunction. Am J Manag Care. 6:2000;S625-S631.
6. Vitezic D., Pelcic J.M. Erectile dysfunction oral pharmacotherapy options. Int J Clin Pharmacol Ther. 40:2002;393-403.
7. Andersson K.E. Pharmacology of erectile function and dysfunction. Urol Clin North Am. 28:2001;233-247.
8. Heaton J.P. Central neuropharmacological agents and mechanisms in erectile dysfunction the role of dopamine. Neurosci Biobehav Rev. 24:2000;561-569.
9. Johri A.M., Heaton J.P., Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res. 13:2001;176-182.
10. Statement on impotence. JAMA. 123:1993;23-27.
11. Saenz de Tejada I., Goldstein I. Diabetic penile neuropathy. Urol Clin North Am. 15:1988;17-22.
12. Trummer H. Oral therapy of erectile dysfunction. Wien Med Wochenschr. 150:2000;11-13.
13. Mannino D.M., Kievens R.M., Flanders W.D. Cigarette smoking an independent risk factor for impotence? Am J Epidemiol. 140:1994;1003-1008.
14. Heaton J.P., Adams M.A., Morales A. A therapeutic taxonomy of treatments for erectile dysfunction an evolutionary imperative. Int J Impot Res. 9:1997;115-121.
15. Thomas J.A. Pharmacological aspects of erectile dysfunction. Jpn J Pharmacol. 89:2002;101-112.
16. Steers W.D. Viagra - after one year. Urology. 54:1999;12-17.
17. Levy A., Crowley T., Gingell C. Non-surgical management of erectile dysfunction. Clin Endocrinol. 52:2000;253-260.
18. Lal S., Kiely M.E., Thavundayil J.X., et al. Effect of bromocriptine in patients with apomorphine-responsive erectile impotence an open study. J Psychiatry Neurosci. 16:1999;262-266.
19. Segraves R.T. New treatment for erectile dysfunction. Curr Psychiatry Rep. 2:2000;206-210.
20. Altwein J.E., Keuler F.U. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int. 67:2001;257-263.
21. Giuliano F., Allard J. Dopamine and male sexual function. Eur Urol. 40:2001;601-608.
22. Heaton JP: Apomorphine: an update of clinical trial results. Int J Impot Res 12(suppl 4): S67-S73, 2000.
23. Rosen R., Riley A., Wagner G., et al. The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 49:1997;822-830.
24. Cappelleri J.C., Rosen R.C., Smith M.D., et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 54:1999;346-351.
25. Lammers P.I., Rubio-Aurioles E., Castell R., et al. Combination therapy for erectile dysfunction a randomized, double blind, unblended active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate, and papaverine hydrochloride in men with moderate to severe erectile dysfunction. Int J Impot Res. 14:2002;54-55.
26. Andersson K.E., Hedlund P. New directions for erectile dysfunction therapies. Int J Impot Res. 14:(suppl 1):2002;S82-S92.
27. Zahran A.R., Simmerman N., Carrier S., et al. Erectile dysfunction occurs following substantia nigra lesions in the rat. Int J Impot Res. 13:2001;255-260.
28. Giuliano F., Allard J. Apomorphine SL preclinical and clinical experiences learned from the first central nervous system-acting ED drug. Int J Impot Res. 14:(suppl 1):2002;S53-S56.
29. Heaton J.P., Altwein J.B. The role of apomorphine SL in the treatment of male erectile dysfunction. BJU Int. 88:(suppl 3):2001;36-38.
30. Dula E., Keating W., Siami P.F., et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology. 56:2000;130-135.